eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

ADVANCE-3 CLINICAL TRIAL

ELIQUIS (apixaban) has demonstrated superior efficacy with a comparable bleeding rate vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total hip replacement surgery1

* Patients received ELIQUIS 2.sup> 5 mg BD plus placebo injections OD. The first dose of oral study medication was given 12–24 hours after closure of surgical wound.1
Patients received subcutaneous enoxaparin 40 mg OD plus placebo tablets BD.1 Subcutaneous study medication was initiated 12 hours (+/- 3 hours) before surgery and continued after surgery, according to investigators’ standard of care.1

Diagnosemethoden

It’s simple to switch your patients to ELIQUIS2

ELIQUIS is available for extended treatment for your patients with DVT / PE2


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ADVANCE-3 = Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism 3   
ARR = Absolute Risk Reduction   
BD = Twice Daily   
CI = Confidence Interval   
CRNM = Clinically Relevant Non-Major   
DVT = Deep Vein Thrombosis   
LMWH = Low Molecular Weight Heparin   
N = Total number of patients in either the ELIQUIS group or the enoxaparin group   
n = Number of patients with event   
OD = Once Daily   
PE = Pulmonary Embolism   
RR = Relative Risk   
RRR = Relative Risk Reduction   
SC = Subcutaneous   
VTE = Venous Thromboembolic Events

* Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVDT PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

References

  1. Lassen MR et al. N Engl J Med 2010; 363: 2487–2498.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.